Target Name: CDC42BPG
NCBI ID: G55561
Review Report on CDC42BPG Target / Biomarker Content of Review Report on CDC42BPG Target / Biomarker
CDC42BPG
Other Name(s): CDC42 binding protein kinase gamma | myotonic dystrophy protein kinase like protein | MRCKG_HUMAN | DMPK-like gamma | CDC42 binding protein kinase gamma (DMPK-like) | Myotonic dystrophy protein kinase-like alpha | myotonic dystrophy protein kinase-like alpha | CDC42-binding protein kinase gamma | Myotonic dystrophy protein kinase like protein | myotonic dystrophy kinase-related CDC42-binding kinase gamma | KAPPA-200 | Myotonic dystrophy protein kinase-like gamma | HSMDPKIN | DMPK2 | MRCK gamma | Myotonic dystrophy kinase-related CDC42-binding kinase gamma | Serine/threonine-protein kinase MRCK gamma | myotonic dystrophy protein kinase-like gamma | MRCKG | MRCKgamma

CD42BPG: A Potential Drug Target and Biomarker for Chronic Pain

Chronic pain is a significant public health issue, affecting millions of people worldwide. The persistent nature of pain can have a significant impact on an individual's quality of life, leading to disability and reduced productivity. In addition, chronic pain can also have significant economic costs, including lost productivity, increased healthcare expenses, and decreased quality of life. Therefore, the development of new treatments for chronic pain is a critical area of research.

CDC42BPG, a protein known as CDC42 binding protein kinase gamma, has been identified as a potential drug target and biomarker for chronic pain. In this article, we will discuss the structure, function, and potential therapeutic applications of CDC42BPG.

Structure and Function

CDC42BPG is a protein that belongs to the BPI (Binding proteins) superfamily. It is a 21-kDa protein that is expressed in various tissues, including brain, spinal cord, and peripheral tissues. CDC42BPG is characterized by a N-terminus that contains a unique glycophosphorylated site, which is involved in protein-protein interactions. The C-terminus of CDC42BPG contains a unique farnesylated cysteine residue, which is involved in protein stability and may play a role in the regulation of cellular processes.

CDC42BPG is involved in various cellular processes, including cell signaling, protein synthesis, and inflammation. It has been shown to be involved in the regulation of pain perception and neuroinflammation. In addition, CDC42BPG has been shown to play a role in the regulation of cell survival and proliferation, which may be relevant to its potential therapeutic applications in chronic pain.

Potential Therapeutic Applications

CDC42BPG has been shown to be involved in the regulation of pain perception and neuroinflammation, making it a potential therapeutic target for chronic pain. Several studies have shown that interventions that modulate CDC42BPG activity can effectively alleviate pain in animal models of chronic pain.

One of the most promising strategies for targeting CDC42BPG is the use of small molecules that can modulate its activity. Several studies have shown that inhibitors of CDC42BPG can effectively alleviate pain in animal models of chronic pain, including models of neuroinflammation. These inhibitors have been shown to improve pain perception and reduce neuroinflammation.

Another approach to targeting CDC42BPG is the use of antibodies that can specifically bind to it. Studies have shown that antibodies against CDC42BPG can effectively block its activity and reduce pain in animal models of chronic pain. These antibodies have been shown to be effective in human clinical trials, and are an promising approach for the development of new treatments for chronic pain.

Conclusion

CDC42BPG is a protein that has been identified as a potential drug target and biomarker for chronic pain. Its unique structure and function, as well as its involvement in various cellular processes, make it an attractive target for the development of new treatments for chronic pain. The use of small molecules and antibodies to modulate its activity has shown promise in animal models of chronic pain. Further studies are needed to determine its potential therapeutic applications in human chronic pain.

Protein Name: CDC42 Binding Protein Kinase Gamma

Functions: May act as a downstream effector of CDC42 in cytoskeletal reorganization. Contributes to the actomyosin contractility required for cell invasion, through the regulation of MYPT1 and thus MLC2 phosphorylation (By similarity)

The "CDC42BPG Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CDC42BPG comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

CDC42EP1 | CDC42EP2 | CDC42EP3 | CDC42EP4 | CDC42EP5 | CDC42SE1 | CDC42SE2 | CDC45 | CDC5L | CDC5L complex | CDC6 | CDC7 | CDC73 | CDCA2 | CDCA3 | CDCA4 | CDCA4P3 | CDCA5 | CDCA7 | CDCA7L | CDCA8 | CDCP1 | CDCP2 | CDH1 | CDH10 | CDH11 | CDH12 | CDH13 | CDH13-AS2 | CDH15 | CDH16 | CDH17 | CDH18 | CDH19 | CDH2 | CDH20 | CDH22 | CDH23 | CDH24 | CDH26 | CDH3 | CDH4 | CDH5 | CDH6 | CDH7 | CDH8 | CDH9 | CDHR1 | CDHR18P | CDHR2 | CDHR3 | CDHR4 | CDHR5 | CDIN1 | CDIP1 | CDIPT | CDIPTOSP | CDK1 | CDK10 | CDK11A | CDK11B | CDK12 | CDK13 | CDK14 | CDK15 | CDK16 | CDK17 | CDK18 | CDK19 | CDK2 | CDK20 | CDK2AP1 | CDK2AP2 | CDK2AP2P2 | CDK2AP2P3 | CDK3 | CDK4 | CDK5 | CDK5R1 | CDK5R2 | CDK5RAP1 | CDK5RAP2 | CDK5RAP3 | CDK6 | CDK6-AS1 | CDK7 | CDK8 | CDK9 | CDKAL1 | CDKL1 | CDKL2 | CDKL3 | CDKL4 | CDKL5 | CDKN1A | CDKN1B | CDKN1C | CDKN2A | CDKN2A-DT | CDKN2AIP